Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PDS Biotechnology Corp Director's Dealing 2017

Aug 24, 2017

34613_dirs_2017-08-24_2d24d298-669e-4355-9332-910959a49883.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-08-23

Reporting Person: MARCHIO ALBERT N II (Chief Accounting & Adm Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-08-23 Common Stock S 1000 $10.39 Disposed 5861 Direct